Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel

Pediatrics

Volumn 125, Issue 6, 2010, Pages 1142-1151

  Reisinger, Keith S ^a   Block, Stan L ^b   Collins Ogle, Michelle ^c   Marchant, Colin ^d   Catlett, Melissa ^e   Radley, David ^e   Sings, Heather L ^e   Haupt, Richard M ^e   Garner, Elizabeth I O ^e  

^a Primary Physicians Research   (United States)

^b Kentucky Pediatric Research Institute   (United States)

^c Maria Parham Medical Center   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adacel; Concomitant; Gardasil; HPV vaccine; Menactra

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION; INJECTION SITE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MONITORING; MULTICENTER STUDY; MUSCLE WEAKNESS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN BRUISING; SYNCOPE;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; CHILD; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; PAPILLOMAVIRUS VACCINES; VACCINES, CONJUGATE;

EID: 77953044008     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2336     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention (CDC). Human papillomavirus (HPV) infection. Available at: www.cdc.gov/hpv. Accessed March 18, 2010
2. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine. 2008;26(49):6244-6257
3. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24
4. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10(2):101-106
5. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008;26(5): 686-696
6. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent HPV (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccine in healthy adolescents 11-17 years of age. Pediatr Infect Dis J. 2010, in press
7. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-3):1-34
8. CDC. Factsheet: meningococcal diseases and meningococcal vaccines. Available at: www.cdc.gov/vaccines/vpd-vac/mening/vacmening-fs.htm. Accessed March 18, 2010
9. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278
10. Sanofi Pasteur. Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra. Available at: www.menactra.com/ pdf/ MKT14520-1R-Menactra.pdf. Accessed March 18, 2010
11. Sanofi Pasteur. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed Adacel. Available at: www.adacelvaccine.com/support- files/ protect/adacel/MKT10772-4R-1pg.pdf. Accessed March 18, 2010
12. Reizenstein E, Hallander HO, Blackwelder WC, Kuhn I, Ljungman M, Mollby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods. 1995; 183(2):279-290
13. Aggerbeck H, Heron I. Improvement of a Vero cell assay to determine diphtheria antitoxin content in sera. Biologicals. 1991; 19(2):71-76
14. Simonsen O, Schou C, Heron I. Modification of the ELISA for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1987; 15:143-157 (Pubitemid 17122046)
15. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4(2):156-167
16. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol. 2005;12:959-969
17. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226
18. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of nonzero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447-1454
19. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-209
20. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-2145
21. Kroger AT. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-15):1-48
22. Giuliano A, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-likeparticle vaccine. J Infect Dis. 2007;196: 1153-1162 (Pubitemid 47580270)
23. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-1868
24. Centers for Disease Control and Prevention. Adolescent immunization what is the public health issue? Available at: www.cdc.gov/NCIRD/ progbriefs/downloads/adolescent.pdf. Accessed March 18, 2010
25. Olsson S-E, Villa LL, Costa R, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine. 2007;25: 4931-4939
26. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/ 16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11):1459-1466
27. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Vaccine. 2009;27(41):5612- 5619